证券代码：688013 证券简称：天臣医疗 公告编号：2026-001 天臣国际医疗科技股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 履约的重大风险及不确定性：本次签订的战略合作协议不涉及金额，具 体合作内容以双方另行签订的合同为准。本协议为双方基于未来合作意向签署的 框架性、原则性协议，不构成对具体合作项目、实施进度或商业成果的实质性承 诺。协议履行过程中，若受行业政策调整、市场环境变化等不可预见因素或不可 抗力影响，可能导致协议无法如期履行或履行效果未达预期。公司将根据协议履 行情况及后续合作进展，按照《上海证券交易所科创板股票上市规则》等相关法 律法规、规范性文件的规定，及时履行信息披露义务，敬请投资者注意投资风险。 对公司业绩的影响：本协议属于框架性协议，预计对天臣国际医疗科技 股份有限公司（以下简称"公司"或"天臣医疗"）2026 年度及未来业绩不构 成直接影响，对公司业绩的具体影响需视下一步具体项目推进和实施情况来确定。 一、战略合作协议签订的 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. to promote innovation and industrialization in medical intelligence and information technology [1] Group 1: Cooperation Details - The cooperation aims to advance intelligent manufacturing of medical devices and consumables, as well as the research and production of medical robots [1] - Key areas of collaboration include medical intelligence and information, smart medical devices, medical robots, market synergy, and brand co-construction [1] Group 2: Agreement Impact - The agreement is effective upon the affixing of official seals by both parties and is expected to guide long-term cooperation [1] - It is anticipated that the agreement will not have a direct impact on the company's performance for the fiscal year 2026 and beyond [1]

Core Insights - The Chinese open stapler market is experiencing a decline, with the market size decreasing from 15.3 billion yuan in 2020 due to the pandemic, and projected to reach 14.1 billion yuan in 2024, a year-on-year decrease of 2.1% [2] - The decline is attributed to the shift towards minimally invasive surgical techniques, with laparoscopic staplers becoming the mainstream due to their advantages such as less trauma and faster recovery [2] - Despite the decline, open staplers still hold irreplaceable value in grassroots medical settings and complex surgeries, indicating a potential stabilization in market size, although their market share is expected to continue decreasing [2] Industry Overview - Open staplers are primarily used in traditional open surgeries, offering advantages such as quick suturing, ease of use, single-use to prevent cross-infection, and fewer complications [3][4] - The types of open staplers include linear staplers, tubular digestive tract staplers, linear cutting staplers, anal staplers, purse-string staplers, curved cutting staplers, and skin staplers, each with specific applications [4] - The industry chain consists of upstream material suppliers, midstream manufacturers, and downstream consumers such as hospitals and clinics [6] Market Dynamics - The number of medical institutions in China is on the rise, projected to reach 1,093,600 by 2024, which will increase the demand for open staplers [8] - The competition in the open stapler market is shifting towards product upgrades and cost control as the market space contracts [10]

天臣医疗关于选举第三届董事会职工代表董事的公告 天臣国际医疗科技股份有限公司于2025年12月29日召开职工代表大会，选举周云女士为公司第三届董事 会职工代表董事，任期至第三届董事会任期届满。周云女士现任公司总裁办主任，持有公司0.03%股 份，与控股股东、实际控制人及其他董事无关联关系，具备董事任职资格。本次选举产生的职工代表董 事将与公司2026年第一次临时股东会选举产生的董事共同组成第三届董事会。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年12月26日收盘，天臣医疗（688013）报收于54.6元，较上周的48.2元上涨13.28%。本周，天 臣医疗12月26日盘中最高价报56.99元。12月24日盘中最低价报46.58元。天臣医疗当前最新总市值39.02 亿元，在医疗器械板块市值排名88/127，在两市A股市值排名3990/5181。 本周关注点 公司公告汇总：选举周云女士为第三届董事会职工代表董事。 公司公告汇总 ...

证券之星消息，截至2025年12月31日收盘，天臣医疗(688013)报收于48.08元，下跌1.7%，换手率 1.83%，成交量1.49万手，成交额7164.74万元。 天臣医疗2025年三季报显示，前三季度公司主营收入2.44亿元，同比上升20.66%；归母净利润7194.58 万元，同比上升68.29%；扣非净利润6620.23万元，同比上升71.85%；其中2025年第三季度，公司单季 度主营收入8766.31万元，同比上升26.4%；单季度归母净利润2373.42万元，同比上升70.74%；单季度 扣非净利润2191.58万元，同比上升72.61%；负债率11.3%，投资收益255.6万元，财务费用-1087.03万 元，毛利率63.22%。天臣医疗（688013）主营业务：专注于高端外科手术吻合器研发创新和生产销 售。 该股最近90天内共有1家机构给出评级，买入评级1家。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 12月31日的资金流向数据方面，主力资金净流出215.67万元，占总成交额3.01%，游资资金净流入 223.95万元，占总成交额3.13%，散户资金净流出8.28 ...

Market Overview - The medical device sector experienced a decline of 0.9% on December 30, with C Jianxin leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the medical device sector included: - Jianerkang (603205) with a closing price of 29.24, up 3.54% [1] - Yuyao Medical (002223) with a closing price of 38.21, up 2.99% [1] - Tianzhihang (688277) with a closing price of 15.30, up 2.62% [1] - Major decliners included: - C Jianxin (688805) with a closing price of 43.10, down 8.61% [2] - Haooubo (688656) with a closing price of 167.23, down 7.66% [2] - Tianchen Medical (688013) with a closing price of 48.91, down 6.86% [2] Capital Flow - The medical device sector saw a net outflow of 516 million yuan from institutional investors, while retail investors contributed a net inflow of 362 million yuan [2][3] - The top stocks by net inflow from institutional investors included: - Yuyue Medical (002223) with a net inflow of 38.55 million yuan [3] - Meihua Medical (301363) with a net inflow of 35.73 million yuan [3] - Maillande (688273) with a net inflow of 33.48 million yuan [3]

证券之星消息，截至2025年12月29日收盘，天臣医疗(688013)报收于52.51元，下跌3.83%，换手率 3.27%，成交量2.65万手，成交额1.42亿元。 12月29日的资金流向数据方面，主力资金净流入54.46万元，占总成交额0.38%，游资资金净流入957.17 万元，占总成交额6.74%，散户资金净流出1011.64万元，占总成交额7.12%。 近5日资金流向一览见下表： 天臣医疗融资融券信息显示，融资方面，当日融资买入1480.5万元，融资偿还1260.93万元，融资净买入 219.57万元，连续3日净买入累计1186.28万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量 0.0股，融券余额0.0万元。融资融券余额2.21亿元。 近5日融资融券数据一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 天臣医疗2025年三季报显示，前三季度公司主营收入2.44亿元，同比上升20.66%；归母净利润7194.58 万元，同比上升68.29%；扣非净利润6620.23 ...

截至2025年12月29日收盘，天臣医疗（688013）报收于52.51元，较前一交易日下跌3.83%，最新总市值 为42.61亿元。该股当日开盘54.5元，最高55.99元，最低52.02元，成交额达1.42亿元，换手率为3.27%。 公司近日发布公告称，天臣国际医疗科技股份有限公司于2025年12月29日召开职工代表大会，选举周云 女士为公司第三届董事会职工代表董事，任期至第三届董事会任期届满。周云女士现任公司总裁办主 任，持有公司0.03%股份，与控股股东、实际控制人及其他董事无关联关系，具备董事任职资格。本次 选举产生的职工代表董事将与公司2026年第一次临时股东会选举产生的董事共同组成第三届董事会。 最新公告列表 《天臣医疗关于选举第三届董事会职工代表董事的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券日报网讯12月29日，天臣医疗发布公告称，选举周云女士为公司第三届董事会职工代表董事。 ...

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]